GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merus Labs International Inc (NAS:MSLI) » Definitions » Equity-to-Asset

Merus Labs International (Merus Labs International) Equity-to-Asset : 0.54 (As of Mar. 2017)


View and export this data going back to 1996. Start your Free Trial

What is Merus Labs International Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Merus Labs International's Total Stockholders Equity for the quarter that ended in Mar. 2017 was $140.06 Mil. Merus Labs International's Total Assets for the quarter that ended in Mar. 2017 was $261.13 Mil. Therefore, Merus Labs International's Equity to Asset Ratio for the quarter that ended in Mar. 2017 was 0.54.

The historical rank and industry rank for Merus Labs International's Equity-to-Asset or its related term are showing as below:

MSLI's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.59
* Ranked among companies with meaningful Equity-to-Asset only.

Merus Labs International Equity-to-Asset Historical Data

The historical data trend for Merus Labs International's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus Labs International Equity-to-Asset Chart

Merus Labs International Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.51 0.53 0.69 0.53

Merus Labs International Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.53 0.53 0.52 0.54

Competitive Comparison of Merus Labs International's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Merus Labs International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus Labs International's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merus Labs International's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Merus Labs International's Equity-to-Asset falls into.



Merus Labs International Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Merus Labs International's Equity to Asset Ratio for the fiscal year that ended in Sep. 2016 is calculated as

Equity to Asset (A: Sep. 2016 )=Total Stockholders Equity/Total Assets
=150.874/286.379
=0.53

Merus Labs International's Equity to Asset Ratio for the quarter that ended in Mar. 2017 is calculated as

Equity to Asset (Q: Mar. 2017 )=Total Stockholders Equity/Total Assets
=140.055/261.132
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merus Labs International  (NAS:MSLI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Merus Labs International Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Merus Labs International's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus Labs International (Merus Labs International) Business Description

Traded in Other Exchanges
N/A
Address
Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Merus Labs International (Merus Labs International) Headlines